Your browser is no longer supported. Please, upgrade your browser.
Settings
DCPH Deciphera Pharmaceuticals, Inc. daily Stock Chart
DCPH [NASD]
Deciphera Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.81 Insider Own0.10% Shs Outstand39.02M Perf Week-5.34%
Market Cap934.14M Forward P/E- EPS next Y-3.52 Insider Trans- Shs Float21.43M Perf Month-9.52%
Income-99.90M PEG- EPS next Q-0.83 Inst Own58.40% Short Float13.99% Perf Quarter7.31%
Sales- P/S- EPS this Y-72.10% Inst Trans5.21% Short Ratio14.51 Perf Half Y-34.19%
Book/sh7.43 P/B3.22 EPS next Y-11.00% ROA-33.00% Target Price48.89 Perf Year4.09%
Cash/sh7.53 P/C3.18 EPS next 5Y21.00% ROE-36.80% 52W Range18.55 - 45.61 Perf YTD14.05%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-47.51% Beta-
Dividend %- Quick Ratio13.20 Sales past 5Y- Gross Margin- 52W Low29.06% ATR1.34
Employees112 Current Ratio13.20 Sales Q/Q- Oper. Margin- RSI (14)33.29 Volatility3.95% 5.47%
OptionableYes Debt/Eq0.00 EPS Q/Q-32.00% Profit Margin- Rel Volume1.06 Prev Close24.46
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume206.60K Price23.94
Recom2.00 SMA20-10.62% SMA50-10.62% SMA200-21.38% Volume219,357 Change-2.13%
Dec-31-18Upgrade B. Riley FBR Neutral → Buy $27 → $34
Sep-25-18Initiated Leerink Partners Underperform
Aug-29-18Initiated Raymond James Outperform $47
Jul-05-18Initiated SunTrust Buy
Jun-19-18Downgrade B. Riley FBR, Inc. Buy → Neutral $43
Feb-16-18Initiated B. Riley FBR, Inc. Buy $43
Oct-23-17Initiated Piper Jaffray Overweight $35
Oct-23-17Initiated Nomura Buy
Oct-23-17Initiated JP Morgan Overweight $30
Oct-23-17Initiated JMP Securities Mkt Outperform $38
Mar-14-19 04:05PM  Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Year-end 2018 Financial Results Business Wire
Mar-06-19 07:20AM  Market Trends Toward New Normal in Exelon, AT&T, United States Cellular, Deciphera Pharmaceuticals, Boyd Gaming, and Argo Group International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire -5.40%
Mar-05-19 06:03AM  Deciphera CEO resigns, Ex-Agios exec to take over American City Business Journals
Mar-04-19 04:05PM  Deciphera Pharmaceuticals, Inc. Announces Retirement of Michael D. Taylor, Ph.D. Business Wire
Feb-07-19 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the 1st Annual Guggenheim Healthcare Talks Idea Forum Oncology Day Business Wire
Jan-17-19 03:50PM  Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table Investor's Business Daily
Jan-16-19 09:09AM  Deciphera Pharmaceuticals Shares March Higher, Can It Continue? Zacks
Jan-07-19 03:47PM  Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today Motley Fool +13.41%
Jan-03-19 07:30AM  Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Carboplatin in Patients with Advanced or Metastatic Solid Tumors Business Wire -8.14%
Jan-02-19 07:30AM  Deciphera Pharmaceuticals Announces Positive, Preliminary, Top-Line Clinical Data for the Ongoing Phase 1 Clinical Study with DCC-3014 and an Update on Future Development Plans Business Wire +7.10%
07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-27-18 07:20AM  Report: Developing Opportunities within AutoZone, Deciphera Pharmaceuticals, Clearwater Paper, Churchill Downs, Whitestone REIT, and ZTO Express (Cayman) Future Expectations, Projections Moving into 2019 GlobeNewswire
Dec-20-18 07:00AM  Deciphera Pharmaceuticals Initiates Pivotal Phase 3 Clinical Study of Ripretinib (DCC-2618) in Second-line Patients with Gastrointestinal Stromal Tumors (INTRIGUE Study) Business Wire
Dec-19-18 11:29PM  Is Deciphera Pharmaceuticals, Inc. (DCPH) A Good Stock To Buy? Insider Monkey -5.31%
Nov-20-18 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the 30th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-15-18 04:20PM  Deciphera Pharmaceuticals Completes Enrollment in the INVICTUS Pivotal Phase 3 Clinical Study of DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors Business Wire +10.45%
Nov-08-18 07:00AM  Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results Business Wire -7.79%
Oct-23-18 08:35AM  New Research Coverage Highlights Griffon, SEACOR, Deciphera Pharmaceuticals, Clearwater Paper, Comtech Telecommunications, and United Natural Foods Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
07:00AM  Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Paclitaxel to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced or Metastatic Solid Tumors Business Wire
Oct-19-18 08:00AM  Deciphera Pharmaceuticals Reports Updated Preliminary Phase 1 Clinical Study Results with DCC-2618 at the European Society of Medical Oncology (ESMO) 2018 Congress Business Wire -18.25%
Sep-25-18 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference Business Wire
Sep-18-18 07:30AM  Deciphera Pharmaceuticals Appoints Daniel C. Martin as Chief Commercial Officer GlobeNewswire
Aug-29-18 02:19PM  Why Raymond James Is Bullish On Deciphera, Dova Pharmaceuticals Benzinga
07:55AM  Report: Exploring Fundamental Drivers Behind CIRCOR International, Duluth, Griffon, Despegar, SEACOR, and Deciphera Pharmaceuticals New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
07:00AM  Deciphera Pharmaceuticals, Inc. to Participate in Citis 13th Annual Biotech Conference Business Wire
Aug-07-18 04:05PM  Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results Business Wire
Aug-01-18 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference Business Wire
Jul-25-18 07:35AM  Analysis: Positioning to Benefit within Xylem, Duluth, Deciphera Pharmaceuticals, Mesabi Trust, Associated Banc-Corp, and AG Mortgage Investment Trust Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jul-15-18 06:16AM  3 Top Stocks That Aren't on Wall Street's Radar Motley Fool
Jun-20-18 04:05PM  Deciphera Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares Business Wire
Jun-19-18 09:34AM  Deciphera Pharma Hit With Sell-Side Downgrade On Valuation After 50% Gain Benzinga
Jun-13-18 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities 2018 Life Sciences Conference Business Wire
Jun-12-18 08:47AM  Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate Benzinga +6.56%
Jun-11-18 06:20PM  Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock Business Wire
Jun-07-18 03:44PM  Here's Why Deciphera Pharmaceuticals Fell as Much as 11.9% Today Motley Fool -13.56%
Jun-06-18 10:31PM  Deciphera Pharmaceuticals Announces Pricing of Public Offering Business Wire
Jun-05-18 08:10AM  Today's Research Reports on Stocks to Watch: Deciphera Pharmaceuticals and Jounce Therapeutics ACCESSWIRE
Jun-04-18 04:12PM  Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire +47.86%
Jun-02-18 09:30AM  Deciphera Pharmaceuticals Reports Updated Interim Phase 1 Clinical Study Results with DCC-2618 at The 2018 American Society of Clinical Oncology Annual Meeting (ASCO) and Provides Additional Clinical and Regulatory Updates on DCC-2618 Business Wire
May-30-18 12:17PM  CORRECTION FROM SOURCE: Xiana Enters into a Long Term Mining Assignment of an Advanced Exploration Property in Castrovirreyna District, Peru Newsfile
10:32AM  Xiana Enters into a Long Term Mining Assignment of an Advanced Exploration Property in Castrovirreyna District, Peru Newsfile
May-29-18 08:30AM  Deciphera Pharmaceuticals Appoints Stephen B. Ruddy, Ph.D. as Chief Technical Officer Business Wire
May-22-18 02:00PM  Xiana to Acquire Producing Copper Operation in Chile and Announces Financing for up to C$20 Million Newsfile -5.66%
May-21-18 08:30AM  Deciphera Pharmaceuticals Expands Board with the Election of Mr. Steven L. Hoerter as a Director Business Wire +7.63%
May-18-18 07:35AM  Market Trends Toward New Normal in CPB, Deciphera Pharmaceuticals, Masonite International, First Internet, Duluth, and Virtus Investment Partners Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-14-18 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences Business Wire +7.49%
May-08-18 04:05PM  Deciphera Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results Business Wire
Apr-25-18 04:01PM  Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 2018 American Society for Clinical Oncology (ASCO) Annual Meeting Business Wire
Apr-17-18 09:00AM  Preclinical Data Demonstrate That Deciphera Pharmaceuticals' DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIST) Compared to Approved and Investigational Agents Business Wire
Apr-16-18 08:00AM  Deciphera Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1 Clinical Trial of DCC-2618 at 2018 American Association for Cancer Research (AACR) Annual Meeting Business Wire -5.63%
Mar-28-18 04:01PM  Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter 2017 Financial Results and Corporate Highlights Business Wire
Mar-23-18 08:25AM  Report: Exploring Fundamental Drivers Behind Goldfield, Dicerna Pharmaceuticals, Deciphera Pharmaceuticals, WesBanco, Carolina Financial, and TriState Capital New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-15-18 08:30AM  Deciphera Pharmaceuticals, Inc. to Report Clinical and Preclinical Data with DCC-2618 at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting Business Wire -6.14%
Feb-16-18 12:59PM  Deciphera Pharma Scores A Sell-Side Recommendation Benzinga
Jan-24-18 08:15AM  Consolidated Research: 2018 Summary Expectations for ShotSpotter, Deciphera Pharmaceuticals, Ryman Hospitality Properties, Community Bank System, InfraREIT, and USANA Health Sciences Fundamental Analysis, Key Performance Indications GlobeNewswire -5.20%
Jan-04-18 07:00AM  Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (INVICTUS study) Business Wire
Jan-03-18 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-18-17 07:00AM  Deciphera Pharmaceuticals, Inc. Added to Russell 2000® Index GlobeNewswire
Nov-28-17 07:00AM  Deciphera Pharmaceuticals, Inc. Announces Orphan Drug Designation from the EMA for DCC-2618 for the Treatment of Gastrointestinal Stromal Tumors GlobeNewswire
Nov-21-17 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-20-17 07:00AM  Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology GlobeNewswire +6.22%
Nov-15-17 09:30AM  Opening Bell, November 15, 2017 CNBC Videos
Nov-14-17 10:00AM  Deciphera Pharmaceuticals, Inc. (Nasdaq: DCPH) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
07:00AM  Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights GlobeNewswire
Nov-13-17 07:40AM  Featured Company News - Deciphera Reported Data Analysis from the Ongoing Phase-1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society ACCESSWIRE
Nov-10-17 07:00AM  Deciphera Pharmaceuticals, Inc. Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society GlobeNewswire
Nov-06-17 08:17AM  Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology GlobeNewswire
Oct-03-17 07:30AM  Deciphera Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares GlobeNewswire
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b trial to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.